Can Boston Scientific's New Approval Boost Sales?
Investors have gotten their money's worth out of Boston Scientific's stock lately. Shares of the medical device maker have surged by more than 30% in the past six months alone, rising higher despite the company's troubles. Sales have fallen into a slump at Boston Scientific, led lower by the company's cardiac rhythm management, or CRM, business, which produces everything from pacemakers to implantable defibrillators. This is an industry on the decline -- Medtronic , a leader in the medical device field, has seen its own CRM sales slump in recent quarters, while Boston Sci rival St. Jude Medical has similarly had its top line hammered by its CRM division's falling revenue.
Boston Scientific is more than just a cardiovascular device maker, however -- and its smaller, growing divisions invite hope for the company's future despite the slump in its core business. In this video, Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss one of Boston Scientific's hot growing businesses and why investors should pay attention to the company's upcoming earnings report to see whether it's making the right moves to turn around its lagging sales.
Boston Scientific's recent rise is the latest example of how health care companies can reward investors with massive gains; however, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Can Boston Scientific's New Approval Boost Sales? originally appeared on Fool.com.
Fool contributor Dan Carroll and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.